Neoplasma, 65, 6, 2018
965
doi:10.4149/neo_2018_171209N808
Uveal melanoma survival rates after single dose stereotactic radiosurgery
A. FURDOVA1,*, P. BABAL2, D. KOBZOVA2, P. ZAHORJANOVA1, K. KAPITANOVA1, M. SRAMKA3, G. KRALIK4, R. FURDA5, V. KRASNIK1
1
Department of Ophthalmology, Faculty of Medicine, Comenius University in Bratislava, Slovakia; 2Department of Pathology, Faculty of Medicine, Comenius University in Bratislava, Slovakia; 3Department of Stereotactic Radiosurgery, St. Elisabeth Cancer Institute, St. Elisabeth University College of Health and Social Work, Bratislava, Slovakia; 4Department of Medical Physics, Faculty of Medicine, Slovak Medical University,
Bratislava, Slovakia; 5Department of Information Systems, Faculty of Management, Comenius University, Bratislava, Slovakia
*Correspondence: afrf@mail.t-com.sk
Received December 10, 2017 / Accepted March 21, 2018
This paper presents the long-term results of single dose stereotactic radiosurgery for intraocular uveal malignant
melanoma, and summarizes the results of the retrospective study in 170 Slovak patients. A group of uveal melanoma
patients (149 choroidal melanoma, 21 ciliary body melanoma) from 20 to 92 years of age with 59 year median were treated
in 2001–2016. There were 81males (47.7%) and 89 females 89 (52.3%). The median overall follow-up time was three years.
The median tumor volume at baseline was 0.5 cm3 (ranging from 0.2 to 1.6 cm3). The therapeutic dose was 35.0 Gy by 99%
of dose volume histogram. The survival after single dose stereotactic radiosurgery was 96% in one year, 93% in two years,
84% in five years, 80% in seven years and 52% in eleven years. Secondary enucleation was necessary for 22 patients because
of secondary glaucoma complication. The enucleation free interval ranged from one to six years. The survival rates in five
year intervals and necessity of secondary enucleation due to complications after single dose stereotactic radiosurgery is
comparable to other techniques.
Key words: uveal melanoma, linear accelerator, stereotactic radiosurgery, survival, intraocular tumor
Uveal melanoma is the most common and the most
aggressive primary intraocular malignancy in adults. The
mean age-adjusted incidence of uveal melanoma in the
United States is approximately 4.3 new cases per million
people, the incidence in Slovakia is from 2 to 6 new cases per
million inhabitants per year [1, 2].
Age and tumor volume (size) were determined prognostic
indicators for uveal melanoma therapy. The molecular profile
of the uveal melanoma differs in cutaneous and mucosal
melanoma.
Ophthalmological examination and diagnostic tools, such
as ultrasound, optical coherence tomography, computed
tomography (CT), magnetic resonance imaging (MRI) and
positron emission tomography (PET/CT) have led to significant advances in the diagnosis of primary uveal melanoma.
Radiotherapy (brachytherapy and other modalities – proton
beam irradiation and stereotactic radiotherapy) has become
the preferred method of treatment for the majority of
patients with uveal melanoma. Stereotactic radiosurgery
(SRS) of extra-cerebral lesions, such as uveal melanoma, has
been used in the last two decades for treatment of small and
medium stage posterior uveal melanoma because it offers
good local control. Survival rates are comparable to other
types of therapy [3–5].
The single dose SRS is a relatively rare method in treatment
of choroidal melanoma. Image fusion of a contrast-enhanced
MRI and CT is used for treatment planning coordinates. This
treatment is used as single dose SRS with one fraction of 35.0
Gy administered with spatial accuracy by collimation.
The team of specialists consists of an ophthalmologist,
neurosurgeon, medical physicist and a radiation oncologist.
All were responsible for SRS planning and image fusion of
a contrast–enhanced MRI and CT images is used for treatment planning coordinates. Fusion of the images from
these imaging techniques is suitable for accurately specifying anatomical structures and differentiating gross tumor
volume (GTV) and mass from healthy tissue and the most
critical adjacent structures (optic chiasm, brain stem, skin of
the head, bilateral optic nerves and lenses). Precise planning
is most important for determining the stereotactic coordinates of radiation beams to be applied in GTV and irradiation of critical structures by inappropriate doses can lead to
loss of vision or other complications and can reduce later
life quality [6].
966
The ability to metastasize hematogenously is well-known
in choroidal melanoma, and this frequently goes to the liver
[7–9]. Patients after both conservative and surgical ocular
treatment are followed-up for metastases in six monthly
intervals by liver function tests, and/or imaging methods.
Survival prognostic factors are; (1) clinical predictors
(tumor maximum elevation, basal diameter, ciliary body
involvement, extra-ocular infiltration), (2) histopathological
predictors (epithelioid melanoma has worse prognosis), and
(3) high mitotic count and genetic predictors. Although
effective local therapies have been developed over the past
30 years, five-year survival rates have not changed, and over
50% of patients develop metastases.
The aim of this study is to determine the length of time
before metastasis diagnosis after stereotactic radiosurgery,
and the rates and sites of metastasis discovered during patient
follow-up.
Patients and methods
We analyzed data in a retrospective study of patients with
intraocular uveal melanoma T1 to T3 stages who underwent
SRS at linear accelerator (Model LINAC C 600 C/D Varian
[Varian Medical Systems Inc., Palo Alto, California, USA]
with 6 MeV photons in 2001–2016. The manuscript does
not report results of experimental investigations on human
subjects due to the Declaration of Helsinki, and our study
was approved by the Ethics Committee at the University
Teaching Hospital in Bratislava.
Treatment protocol. All patients with uveal melanoma
treated in 2001–2016 were included. Patients were not
randomized either to radical (enucleation) or to “conservative” procedures, because treatment was determined exclusively on a patient-to-patient basis. Tumor stage, volume,
maximum elevation, localization, presence of secondary
retinal detachment, general status, age, gender, the functional
tests (visual acuity, perimetry, ultrasound) were all considered. All patients were actively involved in the decision on
their therapeutic procedure after the possible post-operative
complications were discussed.
Data analysis. The tumor volume was calculated using the
formula: volume = π/6 × length × width × height. Tumors
were divided into three groups: small – less than 0.5 cm3,
medium – 0.5 to 1.0 cm3, and large – over 1.0 cm3.
Immobilization of the affected eye was achieved by
surgical fixation of the eye-globe to the stereotactic Leibinger
frame. Sutures were placed under local anesthesia to four
direct extraocular muscles through conjunctiva and through
the lids. The stereotactic frame was fixed to the head and
the sutures were tied to the stereotactic frame. The patient
underwent CT and MRI examination with the immobilized
eye-globe to the frame. The stereotactic treatment planning
after fusion of CT and MRI was optimized according to the
critical structures – lenses, optic nerves and chiasm. Tumor
volume calculation was based on the ROI (region of interest)
A. FURDOVA, et al.
of the tumor. The planned therapeutic dose into the tumor
mass was 35.0 Gy by 99% of DVH (dose volume histogram).
On the sa me afternoon, the patient underwent irradiation at linear accelerator. The doses to the critical structures
were below 8.0 Gy for the optic nerve and the optic disc,
and 10.0 Gy to the anterior segment of the eye due to SRS
planning scheme. Sutures and frame were removed under
local anesthesia.
Follow-up. Patients were followed-up after three months
by an ophthalmologist (biomicroscopy, ophthalmoscopy,
aplanation tonometry, ultrasound, Optical Coherence
Tomography), and sent for orbit MRI after six months.
Following the first visit after stereotactic radiosurgery,
patients were seen by their oncologist every six months for
metastases screening (liver ultrasound, abdominal ultrasound, liver function test; once per year chest X-ray). Since
January 2014, every patient has had a whole body PET/CT
(Positron Emission Tomography) before stereotactic radiosurgery to exclude liver metastases. The disease free interval
was defined as the time from treatment until the development
of metastases. Patients were seen in three monthly intervals
in the first year after the SRS, later in six monthly intervals
following SRS; and five years after SRS they were requested to
attend each year for complete examination.
Statistical methods. We used single linear regression,
basic statistical methods and the non-parametric method to
estimate the probability of survival after given time intervals.
Results
Patients’ characteristics. A total of 170 consecutive charts
of patients with uveal melanoma (149 choroidal melanoma
– 87.6%, 21 ciliary body melanoma – 12.4%) treated with
single dose SRS were reviewed. Patient age ranged from 21
to 90 years with a median of 57 years. The number of males
was 81 (47.7%) and number of females 89 (52.3%). Median
tumor volume at baseline was 0.5 cm3, with range from 0.2
to 1.6 cm3. The therapeutic dose was 35.0 Gy by 99% of
dose volume histogram (DVH). The median of the maximal
dose applied was 49.0 Gy (range from 37.0 to 51.0 Gy). The
number of the small uveal melanomas was 39 (23%), 97 were
medium (57%) and 34 large (20%) (Suppl. Table 1).
Secondary enucleation was necessary in 22 patients
(12.9%) due to secondary glaucoma. In this subgroup, liver
metastasis developed in 20 patients (90.1%) The enucleation
free interval ranged from one to six years, and Figures 1 and 2
demonstrate patient examination findings before the irradiation, planning scheme and enucleated eye-globe.
Survival analysis. The survival time of 170 patients was
from 0.25 to 15 years. The median overall follow-up time
was three years. We calculated three Kaplan-Meier survival
curves. In the first survival curve, the overall survival after
SRS was 96% in one year, 93% in two years, 84% in five years,
80% in seven years and 52% in eleven years (Figure 3A).
The second survival curve compared small and large tumors
UVEAL MELANOMA SURVIVAL RATES
967
Figure 1. The patient’s status in 2014: A) PET/CT finding of patient with ciliary body melanoma before SRS; B) MRI finding with plotted tumor (red)
and critical structures: lens (yellow), optic nerves (green, orange); C) Stereotactic planning scheme.
Figure 2. The patient’s status in 2016: A) patient 2 years after SRS underwent enucleation due to painful secondary glaucoma: external photograph of
anterior segment before enucleation; B) eye-globe after enucleation with extrascleral extension; C) dissected eye-globe.
Figure 3. A) Survival curves – in group of 170 patients with uveal melanoma after SRS; B) survival curves – the comparison of the small and large tumors; C) survival curves – the comparison of the stages T1, T2, and T3; D) Cox regression – survival curves the patient group by gender.
968
(Figure 3B) and the third compared T1, T2, and T3 stages
(Figure 3C).
We calculated one Cox proportional-hazards regression
by gender (Figure 3D). Two predictors were considered:
tumor volume and age of patient at the time of stereotactic
radiosurgery. The calculation results confirmed that only one
predictor, age by male (p=0.0572 with Risk Ratio 1.0488) was
closest to being a significant prognostic factor. However, its
p value was more than 0.05 and there were no other significant prognostic factors in this Cox proportional-hazards
regression for survival analysis. The other calculated predictors were: age by female, p=0.8107 with Risk Ratio 1.0066,
tumor volume by male, p=0.6210 with Risk Ratio 0.4358, and
tumor volume by female, p=0.3103 with Risk Ratio 0.1765.
The analysis indicated that none of the four predictors were
statistically significant by gender comparison.
Follow-up. In the group of patients with small tumors
who developed metastases, the interval after SRS was over
five years, and in the patient group with large melanoma who
developed metastases, the interval after SRS was less than
three years. Finally, tumor volume reduction review after the
initial six months following SRS ranged from 6 to 110 months.
We analyzed acute side effects on the eye-lids and anterior
eye segment following SRS. The SRS planning scheme
ensured that doses to the critical structures were below 8.0 Gy
for the optic nerve (median 2.0 Gy), below 12.0 Gy (median
3.0 Gy) for the optic disc and below 10.0 Gy (median 5 Gy) to
the anterior segment of the eye. Long-term side effects such
as cataracts and maculopathy were noted in patients with
tumors less than 3.0mm from the macula or ciliary body.
Tumor local control was successful in 95% of patients two
years after SRS and in 75% of patients three years after SRS.
Late complications 24 months after SRS were observed:
macular destruction because of scarring around the tumor in
55% patients, optic nerve atrophy in 15%, partial lens opacity
in 30%, total cataract in 5%, vitreous hemorrhage in 5%,
secondary glaucoma in 15%, and central retinal vein thrombosis in 10%. Secondary enucleation was necessary in 22
patients (12.9%) due to secondary glaucoma. Melanoma was
histopathologically verified in all enucleated eyes: spindle
cell type A in 16 (72.7%) patients; spindle cell type B in two
(9.1%) and epitheloid type in four (18.2%) patients. The
BRAF mutation was negative in all these patients.
Discussion
Management of posterior uveal melanoma depends on
tumor location, extent and size, on visual acuity on presentation and on systemic status [10].
The tendency away from enucleation towards eye-globe
sparing techniques is seen in uveal melanoma patient
management. The alternatives are: a) observation, b) transpupillary thermotherapy, c) block-excision, d) endo-resection with pars plana vitrectomy, e) brachy-therapy with a
variety of radioisotopes, f) radiotherapy – proton beam
A. FURDOVA, et al.
irradiation, g) Leksell Gamma Knife and h) stereotactic
radiosurgery [11–13].
Randomized, multi-center clinical trials conducted
by the Collaborative Ocular Melanoma Study (COMS)
group showed no difference in long-term survival rates of
patients treated with plaque radiotherapy or enucleation of
medium-sized tumors (basal diameter <16 mm and apical
height 2.5–10 mm) [14]. There was no mortality benefit
with pre-enucleation radiotherapy for large tumors (basal
diameter ≥16 mm and apical height ≥2 mm or any basal
diameter with apical height ≥10 mm) [15].
Proton beam radiotherapy is another form of radiation
treatment used for posterior uveal melanoma, and this is
comparable to plaque radiotherapy for tumor control, visual
outcome and systemic prognosis [16]. Stereotactic photon
beam radiation therapy using cyber knife, gamma knife or
linear accelerator can also be used in choroidal melanoma
management. The local tumor control, visual outcome and
survival of patients undergoing stereotactic photon beam
radiation therapy are equivalent to those undergoing proton
beam radiotherapy [17].
The COMS study showed no difference in uveal melanomarelated metastasis and death based on gender. However, some
reports suggest a better prognosis in females; with twice the
mortality rate in males in the first 10 years of posterior uveal
melanoma diagnosis [18]. Our study, however, determined
no difference in prognosis due to age.
The efficacy of SRS for uveal melanoma has been proven in
different studies with local tumor control rates reported over
90% [19–21]. High rates of local control can be also achieved
with five-year control rates exceeding 95% in patients treated
with proton-beam irradiation [22]. Reported case series
suggest that SRS can have similar rates for local tumor control,
metastasis, mortality and complications compared to brachytherapy. These findings suggest SRS’s role in the treatment
of selected uveal melanoma cases [23, 24]. The eye-globe
preserving treatment with LINAC based stereotactic irradiation is feasible and well-tolerated in patients with medium
sized and unfavorably located uveal melanoma [25].
There are few large, prospective and randomized trials
with mortality statistics for medium-sized melanomas treated
by brachytherapy, enucleation or SRS [26–28]. The gamma
knife radiosurgery and SRS is a proper alternative in treating
uveal melanoma in patients with lesions which are inappropriate for conventional brachytherapy. Patients receive a
single non-fractionated dose of stereotactic radiation, with
maximum and peripheral doses at 40–75 Gy and 16.5–30 Gy.
Eye retention is one of the main goals of conservative treatment, but secondary enucleation is indicated in some patients
due to complications after irradiation; including secondary
neo-vascular glaucoma [24]. According to presented results,
a single one-day session SRS with 35.0 Gy is recommended
for treating small and medium stage melanoma [28].
Metastatic melanoma has four important prognostic death
factors. The first factor is the size of the tumor: the larger
UVEAL MELANOMA SURVIVAL RATES
the tumor, the worse the prognosis. The second factor is the
location of the tumor. The third factor is the age of the patient
at the time of diagnosis: the older the patient, the worse the
short-term survival prognosis. And the fourth factor is the
extrascleral tumor extension [29]. The obvious disadvantages
of enucleation are eye-globe preservation and useful vision in
patients treated conservatively with SRS.
The limit of metastatic spread is also questionable. Some
observational studies comparing irradiation and enucleation
have reported no significant differences in survival rates [23,
28]. Another study also indicated no significant difference in
comparison of five-year mortality rates in patients treated by
plaque radio-therapy and enucleation [26].
Studies in the past decades have promoted treatment
with proton irradiation, and this can be highly successful in
achieving local control of intraocular melanoma. The overall
rates of metastatic disease are comparable to those observed
after enucleation when this treatment is implemented and it
is further recommended that enucleation should be limited
to patients with large tumors. The stricken eye is unlikely to
be salvaged by non-destructive treatment, such as irradiation.
The refinement of current methods and development
of new techniques should continually improve the positive
outlook of the uveal melanoma patients. The survival strategies in these studies proposed the use of single-dose stereotactic radiotherapy with combined tumor resection. This can
increase tumor control with fewer radiation complications
than mono-treatment with single-dose stereotactic radiotherapy [30, 31].
Multidisciplinary teams must cooperate both in patient
treatment and post-treatment management because
no survival benefit from early metastasis detection has
currently been documented and no effective adjuvant
systemic therapy has been demonstrated to reduce the risk
of metastases [32, 33].
The uveal melanoma TNM stage is an important
prognostic factor. In a study of 7,731 patients with posterior
uveal melanoma based on the American Joint Committee on
Cancer T-category classification, the risk of metastasis and
death increased twofold with each increasing tumor category,
and the 10-year metastatic rate was 15% for T1, 25% for T2,
49% for T3 and 63% for T4 tumors [34]. Kang et al. reported
the overall 5-year survival rate in group of patients after
Gamma Knife surgery for uveal melanoma was 90.9% (20 of
22 patients) [35]. They analyzed patient survival according
to age, sex, tumor volume, and margin dose; however, no
relationship was found among these variables (p>0.05) [35].
Our study revealed the overall 5-year survival rate was 84%,
and no relationship was also found in age, gender, and tumor
volume prediction (p>0.05).
Arnett et al’s study [36] had the following findings;
median age at diagnosis was 70 years and median follow-up
was 26.4 months. Primary ocular melanoma was diagnosed
in 17 (61%) patients (stage T2a–T4e). The average maximum
dose and dose to margin were 41 and 21 Gy, respectively. The
969
mean dose to the optic nerve was 12.6 Gy. The 5-year survival
for subjects presenting with primary ocular melanoma
lesions was 90% and only 1 patient required enucleation after
radiation treatment [36].
This compares with our study where the average maximum
dose was 49 Gy, the overall 5-year survival rate was 84%, and
enucleation was necessary in 12.9%.
It is very hard to clinically differentiate adenocarcinomas
and adenomas derived from pigmented ciliary epithelium
from uveal melanoma. In addition, BRAF gene mutation
has been confirmed in skin malignant melanomas, and
Mori et al.[37] identified BRAF V600E mutations in four
of five adenocarcinoma samples, but not in the 11 uveal
melanoma samples [37]. However, findings in other group
studies failed to confirm that the uveal melanoma should
also contain BRAF mutations because it has similar origin
to skin melanoma. Finally, our study [38] also established negative BRAF results in enucleated eyes with uveal
melanoma [38].
Conclusion
Survival rates in patients with posterior uveal melanoma
treated at linear accelerator are comparable to other treatment methods. According to the results the single dose SRS
with 35.0 Gy is valuable method to treat small and medium
stage uveal melanoma. In this study the survival rates in five
year interval and necessity of secondary enucleation, due to
complications after single dose SRS, is comparable to other
treatment modalities.
Supplementary information is available in the online version
of the paper.
Acknowledgements: This work was supported by APVV-170369 and KEGA 016UK-4/2018.
References
[1]
[2]
[3]
[4]
SINGH AD, TURELL ME, TOPHAM AK. Uveal melanoma:
trends in incidence, treatment, and survival. Ophthalmology 2011; 118: 1881–1885. https://doi.org/10.1016/j.ophtha.2011.01.040
FURDOVA A, OLAH Z, SVETLOSAKOVA Z, KUSENDA P.
[The current state of the evidence of malignant tumors of the
eye and its adnexa (dg. C69) in the Slovak Republic and in
the Czech Republic]. Cesk Slov Oftalmol 2012; 68: 195–201.
FURDOVA A, HORKOVICOVA K, JUSTUSOVA P, SRAMKA M. Is it sufficient to repeat LINEAR accelerator stereotactic radiosurgery in choroidal melanoma? Bratisl Lekárske
Listy 2016; 117: 456–462.
COHEN VM, CARTER MJ, KEMENY A, RADATZ M,
RENNIE IG. Metastasis-free survival following treatment
for uveal melanoma with either stereotactic radiosurgery or
enucleation. Acta Ophthalmol Scand 2003; 81: 383–388.
970
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
A. FURDOVA, et al.
DAMATO B, KACPEREK A, CHOPRA M, CAMPBELL
IR, ERRINGTON RD. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int
J Radiat Oncol Biol Phys 2005; 62: 1405–1411. https://doi.
org/10.1016/j.ijrobp.2005.01.016
FURDOVA A, STRMEN P, WACZULIKOVA I, CHORVATH M, SRAMKA M et al. One-day session LINAC-based
stereotactic radiosurgery of posterior uveal melanoma. Eur
J Ophthalmol 2012; 22: 226–235. https://doi.org/10.5301/
EJO.2011.7733
COLLABORATIVE OCULAR MELANOMA STUDY
GROUP. Assessment of metastatic disease status at death in
435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no.
15. Arch Ophthalmol 2001; 119: 670–676.
DIENER-WEST M, REYNOLDS SM, AGUGLIARO DJ,
CALDWELL R, CUMMING K et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular
Melanoma Study Group Report 23. J Clin Oncol 2004; 22:
2438–2444. https://doi.org/10.1200/JCO.2004.08.194
DIENER-WEST M, REYNOLDS SM, AGUGLIARO DJ,
CALDWELL R, CUMMING K et al. Development of Metastatic Disease After Enrollment in the COMS Trials for
Treatment of Choroidal Melanoma: Collaborative Ocular
Melanoma Study Group Report No. 26. Arch Ophthalmol
2005; 123: 1639–1643.
KALIKI S, SHIELDS CL. Uveal melanoma: relatively rare
but deadly cancer. Eye (Lond) 2017; 31: 241–257. https://doi.
org/10.1038/eye.2016.275
HENDERSON MA, SHIRAZI H, LO SS, MENDONCA MS,
FAKIRIS AJ et al. Stereotactic radiosurgery and fractionated
stereotactic radiotherapy in the treatment of uveal melanoma. Technol Cancer Res Treat 2006; 5: 411–419. https://doi.
org/10.1177/153303460600500409
DIECKMANN K, GEORG D, BOGNER J, ZEHETMAYER
M, PETERSCH B et al. Optimizing LINAC-based stereotactic radiotherapy of uveal melanomas: 7 years’ clinical experience. Int J Radiat Oncol 2006; 66: S47–S52. https://doi.
org/10.1016/j.ijrobp.2006.01.005
MOSCI C, MOSCI S, BARLA A, SQUARCIA S, CHAUVEL
P et al. Proton beam radiotherapy of uveal melanoma: Italian
patients treated in Nice, France. Eur J Ophthalmol 2009; 19:
654–660.
COLLABORATIVE OCULAR MELANOMA STUDY
GROUP. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch
Ophthalmol 2006; 124: 1684–1693. https://doi.org/10.1001/
archopht.124.12.1684
HAWKINS BS, COLLABORATIVE OCULAR MELANOMA STUDY GROUP. The Collaborative Ocular Melanoma
Study (COMS) randomized trial of pre-enucleation radiation
of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am
J Ophthalmol 2004; 138: 936–951. https://doi.org/10.1016/j.
ajo.2004.07.006
GRAGOUDAS ES. Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture. Invest
Ophthalmol Vis Sci 2006; 47: 4666–4673. https://doi.
org/10.1167/iovs.06-0659
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
DUNAVOELGYI R, DIECKMANN K, GLEISS A, SACU S,
KIRCHER K et al. Local tumor control, visual acuity, and
survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys 2011; 81:
199–205. https://doi.org/10.1016/j.ijrobp.2010.04.035
ZLOTO O, PE’ER J, FRENKEL S. Gender differences in
clinical presentation and prognosis of uveal melanoma.
Invest Ophthalmol Vis Sci 2013; 54: 652–656. https://doi.
org/10.1167/iovs.12-10365
MUELLER AJ, TALIES S, SCHALLER UC, HORSTMANN
G, WOWRA B et al. Stereotactic radiosurgery of large uveal
melanomas with the gamma-knife. Ophthalmology 2000;
107: 1381–1387.
KREMA H, SOMANI S, SAHGAL A, XU W, HEYDARIAN M et al. Stereotactic radiotherapy for treatment of
juxtapapillary choroidal melanoma: 3-year follow-up. Br J
Ophthalmol 2009; 93: 1172–1176. https://doi.org/10.1136/
bjo.2008.153429
DIECKMANN K, GEORG D, ZEHETMAYER M, BOGNER
J, GEORGOPOULOS M et al. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience.
Radiother Oncol 2003; 67: 199–206.
MEYER A, LÉVY C, BLONDEL J, D’HERMIES F, FRAU
E et al. [Optic neuropathy after proton-beam therapy for
malignant choroidal melanoma]. J Fr Ophtalmol 2000; 23:
543–553.
SEDDON JM, GRAGOUDAS ES, EGAN KM, GLYNN RJ,
HOWARD S et al. Relative survival rates after alternative
therapies for uveal melanoma. Ophthalmology 1990; 97:
769–777.
GHAZI NG, KETCHERSIDE CS, SHEEHAN J, CONWAY
BP. Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma
Study criteria. Open Access Surg 2008; 1: 21–24. https://doi.
org/10.2147/OAS.S3654
FURDOVA A, SRAMKA M, CHORVATH M, KRALIK G,
KRASNIK V et al. Stereotactic radiosurgery in intraocular
malignant melanoma--retrospective study. Neuro Endocrinol Lett 2014; 35: 28–36.
ADAMS KS, ABRAMSON DH, ELLSWORTH RM, HAIK
BG, BEDFORD M et al. Cobalt plaque versus enucleation for
uveal melanoma: comparison of survival rates. Br J Ophthalmol 1988; 72: 494–497.
SINGH AD, SHIELDS CL, SHIELDS JA. Prognostic factors
in uveal melanoma. Melanoma Res 2001; 11: 255–263.
FURDOVA A, SLEZAK P, CHORVATH M, WACZULIKOVA I, SRAMKA M et al. No differences in outcome between
radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma. Neoplasma 2010; 57: 377–381.
AUGSBURGER JJ, GAMEL JW. Clinical prognostic factors
in patients with posterior uveal malignant melanoma. Cancer 1990; 66: 1596–1600.
KOUTSANDREA C, MOSCHOS MM, DIMISSIANOS M,
GEORGOPOULOS G, LADAS I et al. Metastasis rates and sites
after treatment for choroidal melanoma by proton beam irradiation or by enucleation. Clin Ophthalmol 2008; 2: 989–995.
UVEAL MELANOMA SURVIVAL RATES
[31]
[32]
[33]
[34]
SUESSKIND D, SCHEIDERBAUER J, BUCHGEISTER M,
PARTSCH M, BUDACH et al. Retrospective evaluation of
patients with uveal melanoma treated by stereotactic radiosurgery with and without tumor resection. JAMA Ophthalmol 2013; 131: 630–637. https://doi.org/10.1001/jamaophthalmol.2013.697
TRIOZZI PL, SINGH AD. Adjuvant Therapy of Uveal Melanoma: Current Status. Ocul Oncol Pathol 2014; 1: 54–62.
https://doi.org/10.1159/000367715
FURDOVA A, SRAMKA M, CHORVATH M, KRALIK
G, FURDA et al. Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma.
Melanoma Res 2017; 27: 463–468. https://doi.org/10.1097/
CMR.0000000000000364
SHIELDS CL, KALIKI S, FURUTA M, FULCO E, ALARCON C et al. American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. Ophthalmology 2013; 120:
2066–2071. https://doi.org/10.1016/j.ophtha.2013.03.012
971
[35]
[36]
[37]
[38]
KANG DW, LEE SC, PARK YG, CHANG JH. Longterm results of Gamma Knife surgery for uveal melanomas. J Neurosurg 2012; 117 Suppl: 108–114. https://doi.
org/10.3171/2012.8.GKS121002
ARNETT ALH, REYNOLDS MM, PULIDO JS, PARNEY
IF, LAACK NN. Gamma Knife Stereotactic Radiosurgery for
the Treatment of Primary and Metastatic Ocular Malignancies. Stereotact Funct Neurosurg 2017; 95: 363–368. https://
doi.org/10.1159/000478271
MORI T, SUKEDA A, SEKINE S, SHIBATA S, RYO E et al.
SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms
From Uveal Melanomas. Invest Ophthalmol Vis Sci 2017; 58:
5445–5451. https://doi.org/10.1167/iovs.17-22362
HORKOVICOVA K, MARKUS J, KRCOVA I, BABAL P,
KOBZOVA D et al. [THE BRAF MUTATION AND THE
POSSIBILITIES OF UVEAL MELANOMA METASTASING PROGNOSTIC MARKERS IDENTIFICATION]. Cesk
Slov Oftalmol 2016; 72: 149–156.
UVEAL MELANOMA SURVIVAL RATES - Supplemetal Material
147
Uveal melanoma survival rates after single dose stereotactic radiosurgery
A. FURDOVA1,*, P. BABAL2, D. KOBZOVA2, P. ZAHORJANOVA1, K. KAPITANOVA1, M. SRAMKA3, G. KRALIK4, R. FURDA5, V. KRASNIK1
Supplemental Material
Suppl. Table 1. Follow-up in group of 170 patients.
Follow-up
Period
1 quarter
4 quarters
8 quarters
12 quarters
16 quarters
20 quarters
24 quarters
28 quarters
32 quarters
36 quarters
40 quarters
44 quarters
52 quarters
56 quarters
60 quarters
Grand Total
# of Survived
in LTS
3
6
4
2
7
1
2
1
# of Survived
in MTS
12
12
12
9
18
3
2
2
6
# of Survived
in STS
5
2
4
2
7
1
6
3
1
4
3
1
1
1
1
82
31
31
Total of
Survived
20
20
20
13
32
4
9
4
7
3
5
5
1
1
144
# of Died
LTS
# of Died in
MTS
# of Died in
STS
Total of
Died
2
5
1
5
1
1
1
1
1
1
1
1
1
6
4
6
1
1
1
1
1
2
2
1
15
8
26
1
1
1
1
3
Abbreviations: LTS - Large Tumor Size; MTS - Median Tumor Size; STS - Small Tumor Size.
Grand
Total
20
26
24
19
33
5
10
5
8
5
7
1
5
1
1
170